Buprenorphine depot - Camurus

Drug Profile

Buprenorphine depot - Camurus

Alternative Names: Buprenorphine FluidCrystal® injection depot; CAM 2038

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Camurus
  • Developer Braeburn Pharmaceuticals; Camurus
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Opioid abuse
  • Phase III Pain

Most Recent Events

  • 01 Nov 2017 The US Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee recommends approval of buprenorphine once weekly and once monthly depot injection for the treatment of Opioid abuse
  • 26 Oct 2017 Camurus initiates enrolment in a long-term safety trial for Pain in USA
  • 29 Sep 2017 EMA validates the MAA for buprenorphine depot for Opioid abuse in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top